Table 3.
COVID-19 severity outcome of patients in prediabetes and PCOS cohorts for metformin or levothyroxine (3A) and metformin or ondansetron (3B). Cohen’s D is also reported as an estimate of the effect-size; large effect sizes (absolute value of Cohen’s D > 0.8) are indicated by an asterisk. Values<20 patients are obscured to reduce the risk of patient reidentification.
|
(A) | ||||||||
|---|---|---|---|---|---|---|---|---|
|
PCOS |
Prediabetes |
|||||||
| All | Metformin | Levothyroxine | Cohen’s D | All | Metformin | Levothyroxine | Cohen’s D | |
| n | 282 | 196 | 86 | 3136 | 400 | 2736 | ||
| Mild | 210 (74.5%) | 152 (77.6%) | 58 (67.4%) | −0.233 | 1875 (59.8%) | 310 (77.5%) | 1565 (57.2%) | −0.418 |
| Mild ED | 34 (12.1%) | >20 | <20 | 0.084 | 191 (6.1%) | 31 (7.8%) | 160 (5.8%) | 0.080 |
| Moderate | 36 (12.8%) | >20 | <20 | 0.203 | 849 (27.1%) | 51 (12.8%) | 798 (29.2%) | 0.374 |
| Severe | < 20 | <20 | <20 | 0.079 | 57 (1.8%) | < 20 | > 20 | 0.070 |
| Mortality / hospice | < 20 | < 20 | <20 | 164 (5.2%) | < 20 | > 20 | ||
|
(B) | ||||||||
|---|---|---|---|---|---|---|---|---|
|
PCOS |
Prediabetes |
|||||||
| All | Metformin | Ondansentron | Cohen’s D | All | Metformin | Ondansentron | Cohen’s D | |
| n | 501 | 192 | 309 | 8015 | 397 | 7618 | ||
| Mild | 270 (53.9%) | 158 (82.3%) | 112 (36.2%) | −1.040* | 1383 (17.3%) | 326 (82.1%) | 1057 (13.9%) | −1.963* |
| Mild ED | 93 (18.6%) | 21 (10.9%) | 72 (23.3%) | 0.324 | 889 (11.1%) | 30 (7.6%) | 859 (11.3%) | 0.119 |
| Moderate | 132 (26.3%) | < 20 | > 20 | 0.827* | 4711 (58.8%) | 34 (8.6%) | 4677 (61.4%) | 1.108* |
| Severe | < 20 | < 20 | < 20 | 0.131 | 328 (4.1%) | < 20 | > 20 | 0.179 |
| Mortality/ hospice |
< 20 | < 20 | < 20 | 704 (8.8%) | < 20 | > 20 | ||